Taken together, these data suggest that a reduction in NR4A2-expressing glutamatergic neurons in the hippocampal formation may be associated with AD and that NR4A2 activation may be a promising therapeutic strategy for the treatment of AD [134]. The gene discussed is NR4A2; the disease is Alzheimer disease.